IL280000A - Formulations for reducing tumors and methods of using them - Google Patents

Formulations for reducing tumors and methods of using them

Info

Publication number
IL280000A
IL280000A IL280000A IL28000021A IL280000A IL 280000 A IL280000 A IL 280000A IL 280000 A IL280000 A IL 280000A IL 28000021 A IL28000021 A IL 28000021A IL 280000 A IL280000 A IL 280000A
Authority
IL
Israel
Prior art keywords
methods
tumor reduction
formulations
reduction formulations
tumor
Prior art date
Application number
IL280000A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of IL280000A publication Critical patent/IL280000A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL280000A 2018-07-09 2021-01-07 Formulations for reducing tumors and methods of using them IL280000A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
IL280000A true IL280000A (en) 2021-03-01

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280000A IL280000A (en) 2018-07-09 2021-01-07 Formulations for reducing tumors and methods of using them

Country Status (11)

Country Link
EP (1) EP3820482A4 (de)
JP (1) JP2021530482A (de)
KR (1) KR20220098082A (de)
CN (1) CN112584841A (de)
AU (1) AU2019309757A1 (de)
BR (1) BR112021000279A8 (de)
CA (1) CA3105717A1 (de)
EA (1) EA202190201A1 (de)
IL (1) IL280000A (de)
PH (1) PH12021550033A1 (de)
WO (1) WO2020023191A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022784A2 (pt) 2019-05-14 2022-03-22 Tyme Inc Composições e métodos para tratamento do câncer
CN114945374A (zh) * 2019-12-09 2022-08-26 迪美公司 药物组合物和方法
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713443A2 (de) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensionen von antiretroviralen mitteln für die verbesserte abgabe an das zentrale nervensystem
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2016007741A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
CA3016446A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
EP3820482A4 (de) 2022-03-23
EA202190201A1 (ru) 2021-04-09
CN112584841A (zh) 2021-03-30
KR20220098082A (ko) 2022-07-11
BR112021000279A2 (pt) 2021-04-06
JP2021530482A (ja) 2021-11-11
PH12021550033A1 (en) 2021-09-20
WO2020023191A1 (en) 2020-01-30
AU2019309757A1 (en) 2021-03-04
BR112021000279A8 (pt) 2021-04-20
CN112584841A8 (zh) 2021-06-18
EP3820482A1 (de) 2021-05-19
CA3105717A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
IL281445A (en) Therapeutic nanoparticles and methods for their use
IL276494A (en) Niraprib formulations for children and methods for treating children
IL292810A (en) Therapeutic compounds and methods of use
IL280000A (en) Formulations for reducing tumors and methods of using them
IL276687A (en) Trialkyne coupling agents and methods of using them
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL265955A (en) Therapeutic compounds and methods of use thereof
IL281438A (en) Pyridazinones and methods of using them
EP3099325A4 (de) Verfahren zur behandlung und bildgebung von tumormikrometastasen mittels lichtaktivierbarer immunkonjugate
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Preparations and methods of use
IL285928A (en) Fulvestrant formulations and methods of using them
IL272937A (en) Preparations and methods for the treatment of diseases involving fibrosis
EP3870203A4 (de) Therapeutische kombinationen von tdfrps und zusätzlichen mitteln und verwendungsverfahren
IL286481A (en) Pyridazinones and methods of using them
IL283782A (en) Analosomes and methods of use
IL291730A (en) Protein-macromolecule conjugates and methods for using them
ZA202000502B (en) Cosmetic compositions and methods of use
IL279633A (en) Immunoconjugates targeting ADAM9 and methods of using them
IL274433A (en) Fulvestrant formulations and methods of using them
ZA202207188B (en) Liquid tasimelteon formulations and methods of use thereof
ZA202108213B (en) Klebsiella vaccine and methods of use
EP3600277A4 (de) Zusammensetzungen zur behandlung von arzneimittelresistenten tumoren und verfahren zur verwendung davon
IL276792A (en) Inhaler and methods for using it
GB2589398B (en) Compounds and methods of use